Production (Stage)
Ginkgo Bioworks Holdings, Inc.
DNA
$7.42
$0.639.28%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.76% | -9.71% | -30.81% | -43.45% | -46.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.76% | -9.71% | -30.81% | -43.45% | -46.49% |
| Cost of Revenue | 16.07% | -17.51% | -46.48% | -61.76% | -71.07% |
| Gross Profit | 13.20% | -7.57% | -25.68% | -35.88% | -32.54% |
| SG&A Expenses | -30.06% | -32.22% | -34.37% | -61.93% | -71.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 196.49% | 61.26% | 61.26% | 61.26% | -- |
| Total Operating Expenses | -30.25% | -28.20% | -31.14% | -45.35% | -57.55% |
| Operating Income | 43.58% | 34.58% | 31.27% | 45.84% | 60.05% |
| Income Before Tax | 44.67% | 38.68% | 25.02% | 27.38% | 50.74% |
| Income Tax Expenses | -245.90% | -574.65% | 97.60% | 100.01% | 99.17% |
| Earnings from Continuing Operations | 44.71% | 38.73% | 23.77% | 26.51% | 50.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.71% | 38.73% | 23.98% | 26.65% | 50.34% |
| EBIT | 43.58% | 34.58% | 31.27% | 45.84% | 60.05% |
| EBITDA | 48.25% | 37.15% | 32.48% | 48.38% | 62.61% |
| EPS Basic | 48.34% | 42.17% | 27.78% | 35.80% | 57.60% |
| Normalized Basic EPS | 48.27% | 38.83% | 33.28% | 55.58% | 67.87% |
| EPS Diluted | 48.38% | 42.20% | 28.05% | 35.95% | 57.61% |
| Normalized Diluted EPS | 48.26% | 38.82% | 33.27% | 55.58% | 67.88% |
| Average Basic Shares Outstanding | 7.63% | 6.74% | 6.17% | 8.91% | 12.03% |
| Average Diluted Shares Outstanding | 7.61% | 6.72% | 6.16% | 8.89% | 12.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |